Kestra Medical Technologies Ltd. (KMTS)
NASDAQ: KMTSHealth CareMedical/Dental InstrumentsUSD
Market open · Delayed 15 min · as of Oct 9, 11:50 AM ET
KMTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.57B
- EPS (TTM)
- -$2.67
- Dividend yield
- None
- 52-week range
- 17.34 – 30.00
- Day range
- 25.74 – 26.80
- Volume / Avg
- 25.54K / 357.86K
- Beta
- —
- Shares outstanding
- 59.56M
52-week range
KMTS stock today
On Oct 9, KMTS is trading at $26.41, adding $0.635 (2.46%), versus the S&P 500's 0.47% gain. Shares are 12.0% below their 52-week high of $30.00, set on Oct 27, 2025 and 52.3% above the 52-week low of $17.34, in the middle of the past year's range. KMTS is down 2.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 7.4%.
Kestra Medical Technologies has posted a net loss over the last twelve months (EPS of -$2.67), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kestra Medical Technologies
Company profileKestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Brian Webster
- Headquarters
- Kirkland, WA
- Employees
- 443
- IPO year
- 2025
- Website
- kestramedical.com
Financial highlights
Full financialsIn fiscal 2026, Kestra Medical Technologies generated $95.1 million in revenue, up 59.0% from fiscal 2025, its 2nd consecutive year of revenue growth. Kestra Medical Technologies reported a net loss of $131.6 million, compared with a loss of $113.8 million a year earlier. Gross margin was 51.4% (up from 40.5%) and operating margin -141.6%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue | $95.13M | $59.81M | $27.81M |
| Growth | +59.03% | +115.05% | — |
| Net income | $-131.61M | $-113.81M | $-94.12M |
| EPS (diluted) | $-2.43 | $-5.13 | $-5.07 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$30.29+14.71%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q1 2026)
- Sep 14, 2026
- EPS actual vs est.
- $-0.75 vs —
Kestra Medical Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ATECAlphatec Holdings Inc. | 10.54 | +1.84% | $1.63B | vs KMTS |
| NVCRNovoCure Limited | 14.58 | +2.50% | $1.70B | vs KMTS |
| DRTSAlpha Tau Medical Ltd. | 14.38 | +2.71% | $1.33B | vs KMTS |
| XRAYDENTSPLY SIRONA Inc. | 8.82 | +1.50% | $1.76B | vs KMTS |
| LMATLeMaitre Vascular Inc. | 80.26 | +0.77% | $1.84B | vs KMTS |
| TNDMTandem Diabetes Care Inc. | 16.03 | +2.29% | $1.12B | vs KMTS |
| IRMDiRadimed Corporation | 86.98 | +1.28% | $1.11B | vs KMTS |
| INSPInspire Medical Systems Inc. | 68.22 | +2.29% | $1.97B | vs KMTS |
Indexes, lists and sector
Kestra Medical Technologies stock FAQ
What is Kestra Medical Technologies's stock price today?
KMTS last traded at $26.41 as of Oct 9, 11:50 AM EDT, up 2.46% on the day. Prices are delayed at least 15 minutes.
Who is Kestra Medical Technologies's CEO?
Mr. Brian Webster is the chief executive officer of Kestra Medical Technologies Ltd., which has about 443 employees.
What is the KMTS 52-week high?
The 52-week high for KMTS is $30.00 and the 52-week low is $17.34. The stock is currently 12.0% below its high.